Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96GM5

UPID:
SMRD1_HUMAN

ALTERNATIVE NAMES:
60 kDa BRG-1/Brm-associated factor subunit A; BRG1-associated factor 60A; SWI/SNF complex 60 kDa subunit

ALTERNATIVE UPACC:
Q96GM5; A6NN27; Q92924; Q9Y635

BACKGROUND:
The protein known as SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1, or 60 kDa BRG-1/Brm-associated factor subunit A, is integral to the SWI/SNF chromatin remodeling complexes. These complexes are essential for altering DNA-histone contacts, thereby influencing gene expression. Its role extends to the development of the nervous system, where it facilitates the transition of neural progenitors to mature neurons.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in Coffin-Siris syndrome 11, a disorder marked by significant neurological and developmental challenges, the protein presents a promising target for therapeutic intervention. Exploring the function of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 could lead to breakthroughs in treating this syndrome and enhancing our understanding of neural development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.